Center for InVivo Imaging and Therapy Shared Resources Core

项目总结/摘要-体内成像和治疗中心 体内成像和治疗中心（CIVIT）是SJCCC管理的共享资源， 总体目标是提供尖端的成像和图像引导治疗技术， 临床前癌症建模研究。作为SJCCC战略计划的一部分，HMP，DBSTP，NBTP和CBP 优先考虑增强的动物建模作为其临床前研究工作的核心要求， CIVIT是这些计划的核心。CIVIT在推进SJCCC临床前研究方面发挥着重要作用， 领先的手术和成像专业知识，使计划成员能够随时建模和调查遗传和 脑肿瘤、实体瘤和白血病的原位植入模型。CIVIT与SJCCC成员合作 为他们的临床前研究提供建模和进行实验方面的咨询和技术专业知识， research.核心还提供研讨会，教育用户有关新的临床前成像应用， 技术. CIVIT由NCI R50资助的兽医和生物医学工程师Walter Akers博士指导 拥有超过11年的癌症成像和治疗研究经验。他得到1名工作人员的支持 科学家和6名高技能的研究技术人员提供成像，手术和治疗服务，以及 与SJCCC小组合作规划和执行实验，以确保动物研究在 最高标准。CIVIT对该计划癌症研究的影响体现在： 在高影响力期刊（如Blood）中的合作出版物和关键科学贡献水平（n=5）， Nature Genetics（n=3）和Cancer Cell（n=6）。在本供资期间，1月以来的66份出版物 2013-2017年12月使用了CIVIT，代表28个（42%）项目间和33个（50%） 方案内协作。这些包括来自5个项目中的4个项目的出版物：DBSTP（n=16），HMP （n=25）、CBP（n=34）和NBTP（n=25）。在索引年（2017财年），使用CIVIT的所有调查者中有94% SJCCC成员（49/52）。下一阶段的目标包括升级高频超声波（Vevo 3100，Visualsonics），以提供最先进的图像引导注射和肿瘤体积测量功能 测量;获得具有荧光功能的手术显微镜，以优化脑干O-PDX植入 和图像引导切除小鼠O-PDX肿瘤;以及升级具有BLI能力的IGRT系统 （Muriglo，Xstrahl），以实现用于临床前试验的肿瘤选择性辐射。这些先进技术将 确保对SJCCC项目临床前研究的持续高水平支持。

PROJECT SUMMARY/ABSTRACT— Center for In Vivo Imaging and Therapeutics The Center for In Vivo Imaging and Therapeutics (CIVIT) is an SJCCC-managed Shared Resource with the overarching goal of providing cutting-edge imaging and image-guided therapy technologies to advance preclinical cancer modeling research. As part of the SJCCC Strategic Plan, the HMP, DBSTP, NBTP, and CBP prioritized enhanced animal modeling as a central requirement for their preclinical research endeavors, with CIVIT at the center of these plans. CIVIT plays a major role in advancing SJCCC preclinical research by offering leading surgical and imaging expertise, allowing Program members to readily model and survey genetic and orthotopic-implant models of brain tumors, solid tumors, and leukemias. CIVIT partners with SJCCC members to provide consultative and technical expertise in modeling and conducting experiments for their preclinical research. The core also offers seminars to educate users about new preclinical imaging applications and technologies. CIVIT is directed by Dr. Walter Akers, an NCI R50-funded veterinarian and biomedical engineer with more than 11 years of experience in cancer imaging and therapy research. He is supported by 1 staff scientist and 6 highly skilled research technologists to provide imaging, surgery, and therapeutic services, and partner with SJCCC groups in planning and performing experiments to ensure animal studies are conducted at the highest standard. The impact of the CIVIT on the cancer research of the Programs is evidenced by the high level of collaborative publications and key scientific contributions in high-impact journals such as Blood (n=5), Nature Genetics (n=3), and Cancer Cell (n=6). During the current funding period, 66 publications from January 2013–December 2017 used the CIVIT, representing 28 (42%) interprogrammatic and 33 (50%) intraprogrammatic collaborations. These included publications from 4 of the 5 Programs: DBSTP (n=16), HMP (n=25), CBP (n=34), and NBTP (n=25). During the index year (FY2017), 94% of all investigators using the CIVIT were SJCCC members (49/52). Goals for the next period include upgrading high-frequency ultrasounds (Vevo 3100, Visualsonics) to provide state-of-the-art capabilities for image-guided injections and tumor volume measurement; obtaining a fluorescence-capable surgical microscope to optimize brainstem O-PDX implantation and image-guided resections of O-PDX tumors in mice; and upgrading the IGRT system with BLI capability (Muriglo, Xstrahl) to enable tumor-selective radiation for preclinical trials. These advanced technologies will ensure continued high-level support of the preclinical research of the SJCCC Programs.